The early 1990s has potentially many associations -- the break-up of the Soviet Union, the first Gulf War, the World Trade Center and Oklahoma City bombings, The Lion King, Forest Gump, The Fresh Prince of Bel-Air, "Smells Like Teen Spirit," and the cancellation of the baseball season, to name a few.
But we HIV/ID specialists will always remember that period for something else -- namely, that deaths from AIDS in the United States peaked then, making it an especially challenging time to practice.
With the International AIDS Conference in Washington just starting, the International Antiviral (ahem) Society-USA has revised it's HIV treatment guidelines, updating the 2010 version.
The recent FDA approval of a home HIV antibody test (OraQuick In-Home HIV Test) was covered just about everywhere. It's an oral swab test, takes 20-40 minutes, and will be available over-the-counter.
How big a news story was it?
As I've shared before, I'm no fan of the term "HAART" and do everything I can to stop people from using it.
(I'm a fun guy to have at parties.)
I'm returning to this pet peeve of mine because I realized recently that we've passed a milestone of sorts.
I've written so many times about HIV testing that a complete list of the headlines fills two full web pages.
But since the last entry on the topic was more than a month ago, one might think I've lost interest in the topic.
The single case of HIV cure following allogeneic bone marrow transplant is in the news again, this time because of data just presented at "The International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies" (formerly known as the "HIV Resistance Workshop" -- how's that for rebranding?).
The sun was gleaming on Miami's Biscayne Bay. Palm trees swayed in the gentle breeze and, in the distance, cruise ships were about to set sail for exotic ports. English, Spanish and a dozen other languages drifted through the air as happy people enjoyed the beautiful day. As perfect as it was, the idyllic scene was not all it seemed.
From NIAID, an important clinical trial has been stopped early.
As I'm sure you've heard from your patients -- as I did -- lamivudine (3TC) is now available generically.
Now comes news of the release of several generic formulations of nevirapine (NVP), an effective but always somewhat overshadowed medication. Since its approval way back when in 1996, there has always been a solid reason to pick something else.